Brief: Ceapro Inc - Entered Into A Research Agreement For A Phase 1 Safety And Pharmacokinetic Study With Its Flagship Product Avenanthramide
11/08/2021 14:12
Aug 11 (Reuters) - Ceapro Inc CZO.V :
* CEAPRO INC - ENTERED INTO A RESEARCH AGREEMENT FOR A PHASE
1
SAFETY AND PHARMACOKINETIC STUDY WITH ITS FLAGSHIP PRODUCT
AVENANTHRAMIDE
* CEAPRO - CLINICAL STUDY IS PART OF LONG-TERM FORMAL
COLLABORATION SIGNED WITH MONTREAL HEART INSTITUTE & WILL BE LED
BY JEAN-CLAUDE TARDIF
Source text for Eikon: ID:nGNX2zJzcR
Further company coverage: CZO.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ceapro
See all newsBrief: Aeterna Zentaris Announces Details Regarding Transaction with Ceapro
Brief: Ceapro Receives Final Court Approval For Merger With Aeterna Zentaris
Brief: Aeterna Zentaris And Ceapro Announce Merger Of Equals To Create Diversified Biopharmaceutical Company
Brief: Ceapro Inc. Reports 2023 Third Quarter And Nine-Month Financial Results And Operational Highlights
Brief: Ceapro Initiates Phase 1-2A Study Assessing Avenanthramides For Potential Applications In Inflammation Based Diseases